

## SECUKINUMAB solution for injection (Cosentyx®) for non-radiographic axial spondyloarthritis

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of SECUKINUMAB solution for injection (Cosentyx®) for non-radiographic axial spondyloarthritis.**

### GREY

Secukinumab is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).<sup>1</sup>

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of non-radiographic axial spondyloarthritis should continue to follow national guidance, local pathways and local formulary choices:

- > NICE Guideline NG65: [Spondyloarthritis in over 16s: diagnosis and management](#), last updated 02 June 2017
- > NICE Pathway: [Spondyloarthritis overview](#), last updated 12 June 2020
- > Pan Mersey APC Guideline: [Use of biological agents in the management of ankylosing spondylitis and non-radiographic axial spondyloarthritis](#), 31 January 2018
- > Pan Mersey APC Pathway: [Ankylosing Spondylitis \(AS\) and Non-Radiographic Axial Spondyloarthritis \(Axial SpA\) pathway](#), 28 Nov 2018

### References

1. Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics, [Cosentyx 150 mg solution for injection in pre-filled pen](#), 28 April 2020. Accessed online 09 June 2020.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.